Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era

OBJECTIVES: Diffuse large B‐cell lymphoma (DLBCL) is an aggressive heterogeneous lymphoma with standard treatment. However, 30%‐40% of patients still fail, so we should know which patients are candidates for alternative therapies. IPI is the main prognostic score but, in the rituximab era, it cannot...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur J Haematol
Hlavní autoři: Gutierrez, Antonio, Bento, Leyre, Diaz‐Lopez, Antonio, Barranco, Gilberto, Garcia‐Recio, Marta, Lopez‐Guillermo, Armando, Dlouhy, Ivan, Rovira, Jordina, Rodriguez, Mario, Sanchez Pina, Jose María, Baile, Monica, Martín, Alejandro, Novelli, Silvana, Sancho, Juan‐Manuel, García, Olga, Salar, Antonio, Bastos‐Oreiro, Mariana, Rodriguez‐Salazar, Mª José, Fernandez, Ruben, de la Cruz, Fatima, Queizan, Jose Antonio, González de Villambrosia, Sonia, Cordoba, Raul, López, Andres, Luzardo, Hugo, García, Daniel, Sastre‐Serra, Jordi, Garcia, Juan Fernando, Montalban, Carlos, Cabanillas, Fernando, Rodríguez, Jose
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7217048/
https://ncbi.nlm.nih.gov/pubmed/31804029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13364
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky